Archive for June 2020
ZZ Biotech Announces FDA Fast Track Designation for Stroke Program
HOUSTON, June 12, 2020—ZZ Biotech today announced that the US Food and Drug Administration (FDA) has designated the investigation of the company’s experimental drug 3K3A-APC for the treatment of acute ischemic stroke as a Fast Track development program. ZZ Biotech’s 3K3A-APC is a genetically engineered variant of the naturally occurring activated Protein C, which plays…
Read More